Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
26.16
-0.72 (-2.68%)
At close: Dec 26, 2025, 4:00 PM EST
28.00
+1.84 (7.03%)
After-hours: Dec 26, 2025, 7:46 PM EST
Immunovant Market Cap
Immunovant has a market cap or net worth of $5.3 billion as of December 26, 2025. Its market cap has increased by 24.81% in one year.
Market Cap
5.30B
Enterprise Value
4.78B
1-Year Change
24.81%
Ranking
Category
Stock Price
$26.16
Market Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $5.30B, an increase of 4,162.97%. That is a compound annual growth rate of 77.80%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 26, 2025 | 5.30B | 45.83% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | 4.52B | 404.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 964.31B |
| Johnson & Johnson | 500.60B |
| AbbVie | 406.30B |
| UnitedHealth Group | 296.73B |
| AstraZeneca | 286.29B |
| Novartis AG | 267.64B |
| Merck & Co. | 264.21B |
| Novo Nordisk | 232.28B |